Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized Double-blind Phase 3 Study (KEYNOTE 716)

Brief description of study

The purpose of the study is to see how well the study drug, pembrolizumab, works compared to placebo in keeping your cancer from coming back or spreading. The study is also being done to test the safety of the study drug and to see how well your body handles the study drug.


Clinical Study Identifier: s18-00312
ClinicalTrials.gov Identifier: NCT03553836
Principal Investigator: Anna C Pavlick
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.